Taysha Gene Therapies Liabilities 2024

Taysha Gene Therapies Aktienanalyse

What does Taysha Gene Therapies do?

Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas, focused on discovering and developing gene therapies for severe neurological disorders. The company was founded in 2019 by leading pharmaceutical entrepreneur RA Capital Management and gene therapy developer Dr. Steven Gray. Taysha Gene Therapies' business model is based on the belief that gene therapy has the potential to revolutionize medicine. The company is dedicated to developing gene therapies that can be used to treat rare genetic diseases, particularly pediatric diseases that have had limited or no treatment options. Their goal is to create innovative therapeutic approaches to improve the lives of affected patients and their families. To achieve this, the company conducts extensive research and development work, addressing the challenging questions and challenges in their field. The biggest hurdle in gene therapy development is the need to tailor treatments to the specific defects of individual patients, requiring personalized therapy. Taysha Gene Therapies addresses this issue through the use of AAV gene therapies, which provide a versatile tool and allow the company to diversify. Currently, the company has four different divisions focused on developing gene therapies for rare diseases. Their first priority is TSHA-101, a gene therapy targeting Angelman syndrome, a genetic disorder that occurs in babies and toddlers and can cause epileptic seizures, developmental delays, sleep disorders, and speech problems. Taysha Gene Therapies is also working on therapies for Tay-Sachs and GM1 gangliosidosis, which are also rare and severe diseases. Additionally, the company is developing therapies for Rett syndrome. Taysha Gene Therapies aims to make global progress in the field of neuropsychiatric and neurological disorders by setting new standards and creating innovative concepts. The company collaborates with leading geneticists, scientists, and neurologists to incorporate the latest technologies in gene therapy development. They have the potential to elevate the treatment of rare genetic diseases that have had limited or no treatment options. In their efforts to improve patient care, Taysha Gene Therapies has formed partnerships with other companies and institutions. In March 2020, they established partnerships with UT Southwestern, RCPD, and AveXis to facilitate the exchange of data and expertise on selected treatment options. This collaboration aims to accelerate progress in gene therapy and develop new therapies and technologies that enhance patient treatment and quality of life. Overall, Taysha Gene Therapies is engaged in exciting and innovative work focused on implementing gene therapies for rare genetic diseases. With their innovative approaches to therapy concept development, partnerships with leading institutions, and excellent collaboration with other companies, they aim to make a significant contribution to improving healthcare. Output: Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas. It focuses on discovering and developing gene therapies for severe neurological disorders, particularly rare genetic diseases in children. The company aims to improve the lives of patients and their families through innovative therapies. It collaborates with experts and uses cutting-edge technologies. Taysha Gene Therapies also partners with other organizations to accelerate progress and improve patient care. Its mission is to revolutionize medicine and contribute to healthcare improvement. Taysha Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Taysha Gene Therapies's Liabilities

Taysha Gene Therapies's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Taysha Gene Therapies's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Taysha Gene Therapies's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Taysha Gene Therapies's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Taysha Gene Therapies’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Taysha Gene Therapies stock

What is the level of liabilities of Taysha Gene Therapies this year?

Taysha Gene Therapies has a debt balance of 97.79 M USD this year.

What were the liabilities of Taysha Gene Therapies compared to the previous year?

The liabilities of Taysha Gene Therapies have increased by -21.95% dropped compared to the previous year.

What are the consequences of high debt for investors of Taysha Gene Therapies?

High liabilities can pose a risk for investors of Taysha Gene Therapies, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Taysha Gene Therapies?

Low liabilities mean that Taysha Gene Therapies has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Taysha Gene Therapies affect the company?

An increase in liabilities of Taysha Gene Therapies can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Taysha Gene Therapies affect the company?

A decrease in the liabilities of Taysha Gene Therapies can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Taysha Gene Therapies?

Some factors that can influence the liabilities of Taysha Gene Therapies include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Taysha Gene Therapies so important for investors?

The liabilities of Taysha Gene Therapies are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Taysha Gene Therapies take to modify the liabilities?

To change its liabilities, Taysha Gene Therapies can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Taysha Gene Therapies pay?

Over the past 12 months, Taysha Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Taysha Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Taysha Gene Therapies?

The current dividend yield of Taysha Gene Therapies is .

When does Taysha Gene Therapies pay dividends?

Taysha Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taysha Gene Therapies?

Taysha Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Taysha Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taysha Gene Therapies located?

Taysha Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taysha Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taysha Gene Therapies from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Taysha Gene Therapies pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Taysha Gene Therapies in the year 2023?

In the year 2023, Taysha Gene Therapies distributed 0 USD as dividends.

In which currency does Taysha Gene Therapies pay out the dividend?

The dividends of Taysha Gene Therapies are distributed in USD.